Novo Nordisk A/S Stock Forecast, Price & News

20 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Novo Nordisk A/S in the last twelve months. There are currently 2 sell ratings, 7 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Novo Nordisk A/S stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVO, but not buy additional shares or sell existing shares.
View analyst ratings for Novo Nordisk A/S or view top-rated stocks.

20 brokerages have issued 12 month target prices for Novo Nordisk A/S's stock. Their NVO stock forecasts range from $130.00 to $900.00. On average, they expect Novo Nordisk A/S's share price to reach $682.43 in the next twelve months. This suggests a possible upside of 511.3% from the stock's current price.
View analysts' price targets for Novo Nordisk A/S or view top-rated stocks among Wall Street analysts.

Novo Nordisk A/S's stock was trading at $112.00 at the start of the year. Since then, NVO stock has decreased by 0.3% and is now trading at $111.64.
View the best growth stocks for 2022 here.

Novo Nordisk A/S saw a increase in short interest in June. As of June 15th, there was short interest totaling 2,510,000 shares, an increase of 46.8% from the May 31st total of 1,710,000 shares. Based on an average trading volume of 1,450,000 shares, the days-to-cover ratio is currently 1.7 days.
View Novo Nordisk A/S's Short Interest.

Novo Nordisk A/S is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022.
View our earnings forecast for Novo Nordisk A/S.

Novo Nordisk A/S (NYSE:NVO) issued its earnings results on Friday, April, 29th. The company reported $0.94 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.85 by $0.09. The company had revenue of $6.34 billion for the quarter, compared to analysts' expectations of $5.82 billion. Novo Nordisk A/S had a trailing twelve-month return on equity of 72.67% and a net margin of 33.16%.
View Novo Nordisk A/S's earnings history.

Novo Nordisk A/S announced a Semi-Annual dividend on Wednesday, March 2nd. Stockholders of record on Monday, March 28th will be paid a dividend of $0.741 per share on Tuesday, April 5th. This represents a dividend yield of 1.1%. The ex-dividend date of this dividend is Friday, March 25th. This is a positive change from Novo Nordisk A/S's previous Semi-Annual dividend of $0.56.
View Novo Nordisk A/S's dividend history.

Novo Nordisk A/S(NYSE:NVO) pays an annual dividend of $1.48 per share and currently has a dividend yield of 1.33%. The dividend payout ratio of Novo Nordisk A/S is 44.05%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Novo Nordisk A/S will have a dividend payout ratio of 35.32% next year. This indicates that Novo Nordisk A/S will be able to sustain or increase its dividend.
View Novo Nordisk A/S's dividend history.

372 employees have rated Novo Nordisk A/S CEO Lars Fruergaard Jørgensen on Glassdoor.com. Lars Fruergaard Jørgensen has an approval rating of 92% among Novo Nordisk A/S's employees. This puts Lars Fruergaard Jørgensen in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Novo Nordisk A/S include Johnson & Johnson (JNJ), Eli Lilly and (LLY), Pfizer (PFE), Roche (RHHBY), AbbVie (ABBV), Merck & Co., Inc. (MRK), AstraZeneca (AZN), Abbott Laboratories (ABT), Novartis (NVS), Bristol-Myers Squibb (BMY), Sanofi (SNY), GSK (GSK), CSL (CSLLY), Zoetis (ZTS) and Vertex Pharmaceuticals (VRTX).
View all of NVO's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Novo Nordisk A/S investors own include Gilead Sciences (GILD), AbbVie (ABBV), Pfizer (PFE), NVIDIA (NVDA), Johnson & Johnson (JNJ), Alibaba Group (BABA), QUALCOMM (QCOM), Cisco Systems (CSCO), AT&T (T) and Abbott Laboratories (ABT).

Novo Nordisk A/S trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVO."

Novo Nordisk A/S's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Chemung Canal Trust Co. (0.00%) and Park National Corp OH (0.00%).
View institutional ownership trends for Novo Nordisk A/S.

NVO stock was bought by a variety of institutional investors in the last quarter, including Chemung Canal Trust Co., and Park National Corp OH.
View insider buying and selling activity for Novo Nordisk A/S or or view top insider-buying stocks.

Shares of NVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NVO stock can currently be purchased for approximately $111.64.

Novo Nordisk A/S (NYSE:NVO) has a market capitalization of $262.89 billion and generates $22.40 billion in revenue each year. The company earns $7.60 billion in net income (profit) each year or $3.36 on an earnings per share basis.

Novo Nordisk A/S employs 45,000 workers across the globe.

Novo Nordisk A/S was founded in 1923.

Novo Nordisk A/S's mailing address is Novo Alle, Bagsvaerd G7, 2880. The official website for Novo Nordisk A/S is www.novonordisk.com. The company can be reached via phone at (454) 444-8888, via email at phak@novonordisk.com, or via fax at 45-4449-0555.